Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial

Table 3 pCR analyses in the ITT populations

	P013	Reference pertuzumab	Difference (95% Confidence interval)
Total pCR (ITT)	60 (56.07)	68 (63.55)	−0.07 (− 0.21, 0.06)

For ITT analysis, patients with missing assessments were considered to be nonresponders
Difference = P013- Reference pertuzumab
pCR Pathological complete response

ISSN: 1471-2407